OncoC4 Raises $50 Million in Series B Financing
OncoC4, Inc., a pioneering clinical-stage biotechnology company, has successfully closed a Series B financing round, raising close to $50 million. This significant funding round was spearheaded by GBA Fund, along with support from the company’s co-founders and existing investors such as HM Capital, 3E Bioventures Capital, and Kaitai Capital. This investment will enable OncoC4 to further its clinical development initiatives for its innovative therapies.
The Vision Behind OncoC4
Founded in 2020 by esteemed immunologists Dr. Yang Liu and Dr. Pan Zheng, OncoC4 has quickly established itself in the biotech landscape. The company's expertise in immuno-oncology and translational medicine has set the stage for a comprehensive pipeline of therapies aimed at addressing significant medical needs. Their commitment to innovation is evident in the diverse range of programs they are developing, which have the potential to offer unique solutions in cancer treatment.
Growth and Expansion Plans
Dr. Yang Liu, who serves as the CEO and Chairman of the Board, expressed gratitude for the robust support from investors. He emphasized the company’s strategic objectives: "Our Series B financing round progressed rapidly, and we deeply appreciate our investors' recognition of our Company and continual support. We are focused on rigorously advancing our core pipeline while expanding our business development efforts to bring groundbreaking therapies to patients globally." This perspective showcases OncoC4's ambitions to become a leader in the field by utilizing their resources effectively for research and development.
Innovative Pipeline Focus
The proceeds from this funding will primarily help accelerate clinical trials and research for several pipeline candidates. As OncoC4 forges ahead, the focus remains on therapies with first-in-class and best-in-class potential. The goal is to not only innovate cancer treatments but to also encompass therapies that may address neurodegenerative diseases, expanding their impact on healthcare.
Commitment to Patient Care
At the heart of OncoC4's mission is a commitment to enhancing patient care. The development of novel biologics is aimed at creating innovative solutions for patients afflicted with cancer and other serious diseases. By targeting both newly identified and well-established therapeutic targets, OncoC4 is positioned to make substantial contributions to treatment practices that could save lives.
About OncoC4
OncoC4 operates out of Rockville, Maryland, focusing on harnessing groundbreaking science in the biotech field. Their pipeline includes multiple promising candidates that reflect the company’s dedication to excellence and innovation in therapeutic discovery. With a robust strategy for development, OncoC4 is well-equipped to lead in the biotech sphere and meet the evolving needs of patients.
Engaging with Interested Investors
For those seeking to learn more about OncoC4 and its mission, the Investor Relations department welcomes inquiries. Ryan Cui, Executive Director of Investor Relations, is available for discussions, ensuring that potential and current investors have the resources they need to understand OncoC4's objectives and progress.
Frequently Asked Questions
What is OncoC4's recent funding round about?
OncoC4 has closed a Series B financing round totaling nearly $50 million to advance its cancer treatment pipeline.
Who founded OncoC4?
OncoC4 was founded in 2020 by Dr. Yang Liu and Dr. Pan Zheng, both accomplished immunologists.
What types of diseases does OncoC4 target?
The company develops innovative biologics for the treatment of cancer and neurodegenerative diseases.
What is the primary use of the new funding?
The funds will mainly support the clinical development of OncoC4's pipeline programs.
How can investors contact OncoC4?
Investors can reach out to Ryan Cui, the Executive Director of Investor Relations, for more information.
